查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856474

遺傳性血管性水腫 (HAE) 治療市場按治療類型、藥物類別、給藥途徑、分銷管道和最終用戶分類 - 全球預測，2025-2032 年

Hereditary Angioedema Therapeutics Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，遺傳性血管性水腫 (HAE) 治療市場將成長至 631.5 億美元，複合年成長率為 6.45%。

關鍵市場統計數據
基準年 2024 382.9億美元
預計年份：2025年 407.7億美元
預測年份 2032 631.5億美元
複合年成長率 (%) 6.45%

對重新定義遺傳性血管性水腫 (HAE) 的管理和策略重點的臨床、商業和監管動態進行簡明扼要、綜合性的概述

遺傳性血管性水腫 (HAE) 是一個獨特的治療領域，其特徵是由緩激肽介導的訊號通路失調引起的發作性且可能危及生命的水腫。臨床治療已從以急性期住院治療為主發展為持續性治療，強調快速按需緩解，並結合預防策略以降低發作頻率和嚴重程度。新型標靶治療藥物、不斷改進的給藥途徑以及不斷變化的治療格局，共同影響臨床決策、醫療照護談判以及病患依從性。

近期治療創新、劑量調整和新出現的證據如何改變遺傳性血管性水腫 (HAE) 的臨床路徑和商業性價值提案

過去十年，藥物治療模式、照護方式和患者期望都發生了翻天覆地的變化，這些變化正在重塑遺傳性血管性水腫 (HAE) 的治療系統。治療方法創新已超越傳統的血漿替代療法，發展到生物目標和小分子藥物，這些藥物旨在抑制激肽釋放酶活性或阻斷緩激肽訊號傳導，從而實現按需有效緩解和持續預防。這些進展為臨床醫生提供了新的選擇，但也提高了在真實世界環境中驗證療效、耐受性和依從性的門檻。

近期關稅政策調整將如何影響遺傳性血管性水腫（HAE）治療的供應鏈、生產選擇、臨床管理和取得途徑

貿易政策和關稅框架的調整會對依賴複雜生物製藥或特殊原料的治療藥物的供應鏈經濟、產品供應和策略採購決策產生重大影響。影響中間體、低溫運輸運輸和醫療設備配件的關稅變化會增加製造商的成本結構，並導致不同分銷管道的價格差異。相關人員正在預見這些變化，並重新評估其供應商多元化、區域製造地和庫存策略，以確保依賴時效性治療的患者的治療連續性。

透過分析治療目的、藥理學類別、給藥途徑、分銷管道和最終用戶治療環境，對治療生態系統進行解構，從而為您的策略提供資訊。

這種治療領域細分透過明確治療目的、藥理學、給藥途徑、通路和最終用戶環境，商業性和臨床決策提供框架。根據治療類型，重點關注按需介入和預防策略。按需干預包括緩激肽受體拮抗劑、激肽釋放酶抑制劑、血漿來源的C1抑制劑和重組C1抑制劑，而預防策略包括單株抗體、口服小分子藥物和血漿來源的C1抑制劑。這種治療類型分類闡明了即時症狀控制和長期預防癲癇發作之間的治療權衡，為臨床治療順序和個人化治療方案提供資訊。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 一種基因療法候選藥物有望持久控制遺傳性血管性水腫（HAE）發作
  • 擴大基於真實世界證據的研究，以評估預防性治療方法的長期安全性和有效性
  • 臨床試驗設計中越來越重視以病人為中心的結果指標和生活品質
  • 整合線上治療藥物分發平台，簡化HAE療法的家庭給藥流程
  • 價格壓力和不斷變化的報銷政策影響著新型遺傳性血管性水腫（HAE）療法的可及性
  • 開發具有更長半衰期的新一代單株抗體，用於預防急性HAE發作

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 遺傳性血管性水腫 (HAE) 治療市場（依治療類型分類）

  • 一經請求
    • 緩激肽受體拮抗劑
    • 激肽釋放酶抑制劑
    • 血漿來源的C1抑制劑
    • 重組C1抑制劑
  • 預防
    • 單株抗體
    • 口服小分子
    • 血漿來源的C1抑制劑

9. 依藥物類別分類的遺傳性血管性水腫 (HAE) 治療市場

  • 緩激肽受體拮抗劑
  • 激肽釋放酶抑制劑
  • 單株抗體
  • 血漿來源的C1抑制劑
  • 重組C1抑制劑

10. 遺傳性血管性水腫 (HAE) 治療市場（依給藥途徑分類）

  • 靜脈注射
  • 口服
  • 皮下

11. 依分銷管道分類的遺傳性血管性水腫 (HAE) 治療市場

  • 醫院藥房
  • 零售藥房
  • 專科藥房

12. 依最終使用者分類的遺傳性血管性水腫 (HAE) 治療市場

  • 診所
  • 居家醫療
  • 醫院

13. 各地區遺傳性血管性水腫 (HAE) 治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 按組別分類的遺傳性血管性水腫 (HAE) 治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國遺傳性血管性水腫 (HAE) 治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Takeda Pharmaceutical Company Limited
    • CSL Behring AG
    • BioCryst Pharmaceuticals, Inc.
    • Pharming Group NV
    • Ionis Pharmaceuticals, Inc.
Product Code: MRR-742BD517F714

The Hereditary Angioedema Therapeutics Market is projected to grow by USD 63.15 billion at a CAGR of 6.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 38.29 billion
Estimated Year [2025] USD 40.77 billion
Forecast Year [2032] USD 63.15 billion
CAGR (%) 6.45%

A concise integrated overview of clinical, commercial, and regulatory dynamics that are redefining hereditary angioedema management and strategic priorities

Hereditary angioedema remains a distinct therapeutic area characterized by episodic, potentially life-threatening swelling driven by dysregulated bradykinin-mediated pathways. Clinical management has evolved from acute, hospital-centered interventions to a continuum that emphasizes rapid on-demand relief combined with proactive prophylactic strategies to reduce attack frequency and severity. The interplay between novel targeted therapies, evolving administration routes, and shifting care settings now shapes clinical decision-making, payer negotiations, and patient adherence patterns.

This executive summary synthesizes contemporary clinical, commercial, and regulatory dynamics that are reshaping how clinicians, manufacturers, and health systems approach hereditary angioedema. It highlights transformational therapeutic innovations, evaluates the ripple effects of recent trade policy adjustments, and distills segmentation and regional trends that influence go-to-market tactics. The goal is to provide decision-makers with a concise, integrated perspective that supports evidence-driven prioritization of investments, partnerships, and product positioning across both acute and preventive care pathways.

How recent therapeutic innovations, administration shifts, and evidence generation are collectively transforming clinical pathways and commercial value propositions in hereditary angioedema

The past decade has witnessed transformative shifts across drug modalities, care delivery, and patient expectations that are converging to reshape the hereditary angioedema ecosystem. Therapeutic innovation has progressed beyond traditional plasma-derived replacement approaches to include targeted biologics and small molecules designed to interrupt kallikrein activity or block bradykinin signaling, enabling both efficacious on-demand relief and sustained prophylaxis. These advances have introduced new choices for clinicians, but they have also raised the bar for demonstrating comparative effectiveness, tolerability, and real-world adherence.

Concurrently, patient-centric delivery innovations-such as oral prophylactic agents and subcutaneous formulations-have accelerated the movement of care from inpatient settings into clinics and home environments. This decentralization increases the importance of patient education, remote monitoring, and support programs that ensure correct administration and timely escalation of care during breakthrough attacks. Payers and health systems now demand robust value narratives that combine clinical outcomes with evidence of reduced acute care utilization. As a result, manufacturers are investing in longitudinal evidence generation, patient-reported outcomes, and economic modeling to substantiate therapeutic differentiators and to support formulary positioning.

Finally, collaborative pathways between academic centers, specialty pharmacies, and advocacy groups are amplifying real-world data capture and enabling pragmatic comparative analyses. Innovations in registry design, digital symptom tracking, and pharmacovigilance are creating richer evidence streams that inform treatment sequencing and guideline evolution. Taken together, these shifts signal a maturing therapeutic landscape where scientific innovation is tightly linked to delivery model redesign and value demonstration.

Assessing how recent tariff policy adjustments can ripple through supply chains, manufacturing choices, clinical administration, and access pathways for hereditary angioedema treatments

The introduction of adjustment in trade policy and tariff frameworks can materially influence supply chain economics, product availability, and strategic sourcing decisions for therapeutics that rely on complex biologic production or specialized raw materials. Tariff changes affecting intermediate components, cold-chain transport, and medical device accessories elevate cost structures for manufacturers and can introduce variability in pricing across distribution channels. Anticipating such shifts, stakeholders are reevaluating supplier diversification, regional manufacturing footprints, and inventory strategies to preserve continuity of care for patients dependent on time-sensitive therapies.

Manufacturers that source critical inputs internationally may respond by regionalizing production or establishing contingency inventory hubs to mitigate the operational impact of tariff-driven cost pressures. These actions, while stabilizing supply, require capital allocation and lead-time adjustments that influence product launch sequencing and contracting negotiations with payers and providers. For clinically administered treatments, increased logistics complexity can also affect hospital and clinic procurement practices, leading institutions to favor therapies with simpler storage and handling requirements when clinically appropriate.

Moreover, tariffs can indirectly shape competitive dynamics by altering total delivered cost across routes of administration. For example, therapies that reduce dependence on intravenous administration and complex hospital services may present an advantage in environments where tariffs elevate the cost of imported infusion-related components. In parallel, specialty pharmacies and home care providers will need to adapt their procurement and reimbursement strategies to reflect any incremental cost burdens, working with manufacturers and payers to preserve patient access while maintaining sustainable margins. Ultimately, productive engagement between industry, policy stakeholders, and supply chain partners will be essential to navigate tariff-driven disruptions and to safeguard stable access to lifesaving therapeutics.

Deconstructing the therapeutic ecosystem through treatment intent, pharmacologic class, administration routes, distribution channels, and end-user care settings to inform strategy

Segmentation in this therapeutic area frames commercial and clinical decision-making by delineating treatment intent, pharmacology, administration route, distribution pathways, and end-user environments. Based on treatment type, emphasis is placed on both On Demand interventions and Prophylaxis strategies; On Demand interventions include bradykinin receptor antagonists, kallikrein inhibitors, plasma derived C1 inhibitors, and recombinant C1 inhibitors, while Prophylaxis strategies encompass monoclonal antibodies, oral small molecules, and plasma derived C1 inhibitors. This treatment-type taxonomy clarifies the therapeutic trade-offs between immediate symptomatic control and long-term attack prevention, informing clinical sequencing and patient-tailored regimens.

Based on drug class, analyzers consider bradykinin receptor antagonists, kallikrein inhibitors, monoclonal antibodies, plasma derived C1 inhibitors, and recombinant C1 inhibitors as distinct mechanisms with different safety profiles, administration requirements, and evidence expectations. These pharmacologic categorizations drive differential value messages to payers and clinicians, particularly when head-to-head comparative evidence remains limited. Based on route of administration, distinctions among intravenous, oral, and subcutaneous formats materially influence site-of-care economics, patient adherence, and design of support services, since intravenous therapies often require facility-based delivery whereas oral and subcutaneous options facilitate clinic or home administration.

Distribution channel segmentation further shapes commercial execution and access pathways, with hospital pharmacies, retail pharmacies, and specialty pharmacies each playing specific roles in dispensing, reimbursement navigation, and patient support. Hospital pharmacies remain central for acute administration and inpatient management, retail pharmacies provide convenience for routine refills and community access, and specialty pharmacies deliver care coordination and claims expertise for high-cost or complex therapies. Finally, end-user segmentation across clinic, home care, and hospital settings underscores the growing importance of decentralized care models, where home infusion or self-administered prophylaxis requires robust training, monitoring, and safety net arrangements to preserve clinical outcomes and patient confidence.

How regional healthcare architectures, payer processes, and care delivery models drive differentiated adoption patterns across the Americas, EMEA, and Asia-Pacific

Geography continues to shape clinical practice patterns, regulatory pathways, reimbursement models, and adoption velocity across hereditary angioedema therapeutics. In the Americas, established specialty care networks, a strong private-sector payer presence, and concentrated centers of expertise often accelerate uptake of novel prophylactic agents and support robust specialty pharmacy integration. Clinical pathways in this region emphasize rapid on-demand access paired with growing home-based prophylaxis programs, reflecting both patient preference and system incentives to reduce acute care utilization.

In Europe, Middle East & Africa, heterogeneity in national health system structures, access criteria, and procurement mechanisms results in variable adoption timelines. Countries with centralized health technology assessment processes commonly require comprehensive evidence packages that demonstrate real-world effectiveness and cost implications, while other jurisdictions may prioritize managed access arrangements or named-patient programs to bridge access during evidence development. Across these markets, clinician networks and regional centers of excellence play a pivotal role in shaping guideline interpretation and treatment sequencing.

Asia-Pacific presents a diverse landscape where regulatory modernization, expanding specialty care capacity, and rising patient advocacy are accelerating interest in both on-demand and prophylactic options. In several markets, the growth of outpatient infusion centers, specialty pharmacy capabilities, and digital health platforms is enabling broader adoption of self-administration approaches. Across all regions, cross-border collaborations, multinational clinical registries, and real-world evidence platforms are increasing the comparability of outcomes and informing multinational market entry strategies and value demonstration efforts.

Examining how innovators and incumbents align clinical differentiation, distribution partnerships, and real-world evidence to secure durable commercial advantage

Company strategies in hereditary angioedema increasingly center on differentiated clinical profiles, delivery innovations, and evidence generation that supports payer and provider value propositions. Established biopharmaceutical companies with experience in biologics tend to leverage scale, integrated manufacturing, and existing commercial networks to introduce monoclonal antibodies and recombinant enzymes, while smaller biotechnology firms focus on highly targeted mechanisms, novel oral molecules, or formulation improvements that enable subcutaneous use and home administration. Strategic partnerships between platform innovators and specialty distributors are common, as they combine clinical differentiation with execution capabilities across complex supply chains.

Commercial playbooks emphasize curated patient journeys, including adherence support, nurse-led training for self-administration, and outcomes tracking that can validate therapeutic benefits in routine practice. Companies are also prioritizing lifecycle management initiatives-such as new formulations, label expansions, and pediatric data generation-to extend clinical utility and address underserved subpopulations. In competitive landscapes where multiple classes coexist, successful firms articulate clear comparative hypotheses and invest in head-to-head or pragmatic registries to substantiate real-world advantages. Finally, manufacturing resilience and supply chain transparency are treated as strategic differentiators, particularly for therapies requiring cold chain logistics or plasma-derived inputs.

Actionable tactics for aligning clinical evidence, decentralized delivery, supply chain resilience, and payer engagement to accelerate adoption and sustain access

Industry leaders should prioritize an integrated approach that aligns therapeutic differentiation with pragmatic delivery models and robust evidence generation. First, invest in longitudinal real-world studies and patient-reported outcome instruments to demonstrate not only clinical efficacy but also reductions in healthcare utilization and improvements in daily functioning. These data assets strengthen contracting conversations with payers and create a defensible narrative for preferential placement when clinical differences are nuanced. Second, optimize product formats and support services to enable decentralization of care-developing training modules, telehealth support, and home administration checklists will reduce barriers to adoption and improve adherence.

Third, proactively assess supply chain exposure to tariff shifts and consider regional manufacturing or inventory buffering for critical components to preserve continuity of care. Engaging early with logistics partners and integrating scenario planning into commercial launch timelines will mitigate disruption risk. Fourth, establish targeted payer engagement strategies that map value stories to specific distribution channels and end-user contexts; specialty pharmacies and hospital procurement teams require differentiated evidence and operational assurances to endorse new therapies. Finally, pursue collaborative research with centers of excellence and patient advocacy organizations to accelerate enrollment in registries and to refine outcome measures that matter most to patients and payers, reinforcing both clinical and commercial positioning.

A transparent mixed-methods evidence synthesis combining clinical literature, stakeholder interviews, registries, and trade analyses to support strategic decision-making

The research underpinning this analysis combined a structured review of peer-reviewed clinical literature, regulatory documents, and guidelines with expert interviews across clinical, payer, and commercial stakeholders. Data abstraction prioritized therapeutic mechanism, administration route, documented outcomes, safety signals, and patterns of care delivery. Real-world insights were synthesized from clinical registries and anonymized claims narratives to illuminate treatment pathways and site-of-care transitions without relying on proprietary market sizing datasets.

Qualitative inputs were validated through cross-stakeholder discussions to reconcile clinical practice variations and to surface emergent trends in patient preferences and distribution logistics. Supply chain and tariff-related analyses drew from customs regimes, trade policy announcements, and industry operational reports to characterize plausible impacts on manufacturing and distribution. Throughout the methodology, emphasis was placed on triangulating evidence sources, documenting assumptions, and highlighting areas where data gaps warrant targeted post-market studies or registries to inform long-term strategy.

Summarizing why integrated clinical innovation, supply chain resilience, and real-world evidence are essential to translate therapeutic advances into sustained patient access

The therapeutic landscape for hereditary angioedema is at an inflection point where mechanistic innovation, administration flexibility, and new evidence paradigms converge to create differentiated care pathways. Clinicians now have a broader armamentarium to tailor interventions to individual patient needs, balancing immediate on-demand interventions against longer-term prophylactic strategies that can improve quality of life. At the same time, commercial success increasingly depends on demonstrating value beyond controlled trials-through real-world effectiveness, reduced acute care dependency, and patient-centered outcomes.

Operational resilience is equally vital: manufacturers and distributors must manage supply chain complexity, adapt to policy shifts, and ensure that evolving formulations reach patients in clinic and home settings reliably. Stakeholders who integrate clinical, logistical, and economic perspectives into a unified strategy will be best positioned to translate therapeutic advances into sustainable patient benefit and commercial viability. Ongoing collaboration across clinicians, payers, advocacy groups, and manufacturers will be essential to refine guidelines, capture meaningful outcomes, and expand equitable access to innovative therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of gene therapy candidates aiming to provide durable control of hereditary angioedema attacks
  • 5.2. Expansion of real world evidence studies evaluating long term safety and efficacy of prophylactic therapies
  • 5.3. Increasing focus on patient centric outcome measures and quality of life in clinical trial design
  • 5.4. Integration of online treatment dispensing platforms to streamline home administration of HAE therapies
  • 5.5. Pricing pressure and evolving reimbursement policies impacting access to novel hereditary angioedema treatments
  • 5.6. Development of next generation monoclonal antibodies with extended half life for acute HAE episode prevention

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hereditary Angioedema Therapeutics Market, by Treatment Type

  • 8.1. On Demand
    • 8.1.1. Bradykinin Receptor Antagonist
    • 8.1.2. Kallikrein Inhibitor
    • 8.1.3. Plasma Derived C1 Inhibitor
    • 8.1.4. Recombinant C1 Inhibitor
  • 8.2. Prophylaxis
    • 8.2.1. Monoclonal Antibody
    • 8.2.2. Oral Small Molecule
    • 8.2.3. Plasma Derived C1 Inhibitor

9. Hereditary Angioedema Therapeutics Market, by Drug Class

  • 9.1. Bradykinin Receptor Antagonist
  • 9.2. Kallikrein Inhibitor
  • 9.3. Monoclonal Antibody
  • 9.4. Plasma Derived C1 Inhibitor
  • 9.5. Recombinant C1 Inhibitor

10. Hereditary Angioedema Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Hereditary Angioedema Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Specialty Pharmacies

12. Hereditary Angioedema Therapeutics Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Hereditary Angioedema Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hereditary Angioedema Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hereditary Angioedema Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Takeda Pharmaceutical Company Limited
    • 16.3.2. CSL Behring AG
    • 16.3.3. BioCryst Pharmaceuticals, Inc.
    • 16.3.4. Pharming Group N.V.
    • 16.3.5. Ionis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLA